Gland Pharma Q4 Results 2025: Profit Dips 3% YoY to Rs 187 Crore, EBITDA Down 3%, 1800% Dividend Announced

Gland Pharma announced its fourth-quarter (Q4) financial results for the fiscal year 2024-25 on Tuesday, May 20, revealing a slight decline in both consolidated revenue and profit after tax (PAT).

Gland Pharma Q4 Results 2025

The company's consolidated PAT for Q4 FY25 stood at Rs187 crore, a 3% decrease from Rs 192 crore reported in the same quarter of the previous year. Revenue from operations also saw a 7% year-on-year decline, amounting to Rs 1,425 crore compared to Rs 1,538 crore in Q4 FY24.

When compared to the preceding quarter, Gland Pharma's revenue increased by 3%, and PAT saw a 9% rise, indicating a positive sequential performance.

"In Q4 FY25, our consolidated revenue reached INR 14,249 million, with a healthy EBITDA margin of 24%. On the base business, the EBITDA margin expanded to 38%, driven by volume traction in our U.S. portfolio and high-margin new product launches. Cenexi posted modest sequential improvement in revenue and gross margin, and we remain firmly committed to its turnaround," announced Gland Pharma Chief Executive Officer (CE0).

Gland Pharma Q4 EBITDA

On the operational front, the pharma company's earnings before interest, tax, depreciation, and amortisation (EBITDA) decreased by 3% to Rs 348 crore, down from Rs 359 crore in the corresponding quarter of the previous year. However, the EBITDA margin experienced a slight improvement, rising to 24% from 23% in Q4 FY24.

Gland Pharma Earnings FY2025: Segment-Wise Performance

During the quarter, the company allocated Rs 50.3 crore to research and development (R&D), representing 4.9% of its revenue. For the full fiscal year, R&D expenditure totaled Rs 1,922 crore, accounting for 4.7% of revenue.

In Q4 FY25, Gland Pharma filed five Abbreviated New Drug Applications (ANDAs), with seven receiving approval. Over the course of FY25, the company submitted a total of 24 ANDAs and secured 32 approvals, bringing its cumulative total to 371 ANDA filings in the United States (U.S.), with 318 approved and 53 pending.

Pharma Stock Dividend Announcement: Cash Payout and Record Date Details

The Board of Directors of Gland Pharma has recommended a final dividend of Rs 18 per equity share of Rs 1 each for the financial year 2024-25, subject to shareholder approval at the upcoming Annual General Meeting (AGM). If approved, the dividend will be paid within 30 days from the date of the 47th AGM.

Gland Pharma Dividend Record Date: The record date for determining eligibility for the final dividend is Thursday, August 14, 2025.

The company said, "The record date for the purpose of determining the members eligible to receive the final dividend for the financial year ended March 31, 2025, is Thursday, August 14, 2025."

Company Overview

Gland Pharma is a Hyderabad-based global pharmaceutical company specializing in the development and manufacturing of generic injectable medicines. With a strong presence in over 60 countries, the company focuses on providing high-quality, affordable injectable therapies to healthcare providers worldwide.